Connect your AI

Supernus Pharmaceuticals SUPN Price / earnings

Price / earnings at other companies

AbbVieABBV

105.8×+17.5×

Zevra Therapeutics, Inc.ZVRA

4.4×—

Acadia PharmaceuticalsACAD

10.1×-2.0×

Catalyst PharmaceuticalCPRX

13.7×-1.3×

Amneal Pharmaceuticals, Inc.AMRX

32.5×—

Neurocrine BiosciencesNBIX

19.8×-16.3×

Other financials

Income statement

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

Market cap$2.62B+45.0%

Enterprise value$2.47B+43.5%

P/S3.4×+0.7×

Profitability

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

market cap/net income=27.5×

Based on the most recent quarter.

The official record: Supernus Pharmaceuticals’s 10-Q, filed August 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Supernus Pharmaceuticals's price / earnings?: Supernus Pharmaceuticals (SUPN) reported price / earnings of 27.5× in Q2 2025.
How has Supernus Pharmaceuticals's price / earnings changed year-over-year?: Supernus Pharmaceuticals's price / earnings decreased by 90.2% year-over-year, from 279.8× to 27.5×.
What is the long-term trend for Supernus Pharmaceuticals's price / earnings?: Over 4 years (2020 to 2024), Supernus Pharmaceuticals's price / earnings has grown at a 26.7% compound annual growth rate (CAGR), from 10.5× to 27×.
What does price / earnings mean?: Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.